Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1433-8726
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer ; day:27 ; month:8 ; year:2022 ; pages:1-11
World journal of urology ; (27.8.2022), 1-11
- Creator
-
Chen, Kenneth
Kostos, Louise
Azad, Arun A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00345-022-04135-8
- URN
-
urn:nbn:de:101:1-2022111521062164956474
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chen, Kenneth
- Kostos, Louise
- Azad, Arun A.
- SpringerLink (Online service)
Other Objects (12)
How I Treat Metastatic Hormone-Sensitive Prostate Cancer?
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
Correction to: Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
New directions in growth hormone therapy
CAPN2 promotes apalutamide resistance in metastatic hormone-sensitive prostate cancer by activating protective autophagy
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
New directions of systemic functional linguistics
Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
Impact of time to metastatic disease onset and extent of disease volume across metastatic hormone-sensitive and castration-resistant prostate cancer
How I Treat Metastatic Hormone-Sensitive Prostate Cancer?
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
Correction to: Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
New directions in growth hormone therapy
CAPN2 promotes apalutamide resistance in metastatic hormone-sensitive prostate cancer by activating protective autophagy
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
New directions of systemic functional linguistics
Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
Impact of time to metastatic disease onset and extent of disease volume across metastatic hormone-sensitive and castration-resistant prostate cancer
How I Treat Metastatic Hormone-Sensitive Prostate Cancer?
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
Correction to: Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
New directions in growth hormone therapy
CAPN2 promotes apalutamide resistance in metastatic hormone-sensitive prostate cancer by activating protective autophagy
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
New directions of systemic functional linguistics
Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer